Category - Developments

Developments

111 Inc. in pact with Jilin Baiyi Doctor Group for internet medical services

111 Inc. (NASDAQ:YI) and Jilin Baiyi Doctor Group Management entered into a strategic partnership to leverage the capabilities of 111’s digital platform to provide SMART-enabled healthcare services and doctor...

February 5, 2021

Developments

FDA clears Soliton RAP technology for cellulite improvement

The FDA cleared Soliton’s (NASDAQ:SOLY) Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Soliton’s rapid-pulsed technology safely and comfortably breaks apart the...

February 1, 2021

Developments

Titan Pharma posts positive early study results for JT-09 ProNeura program

Titan Pharmaceuticals (NASDAQ:TTNP) announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor (KOR). JT-09 is being developed...

February 1, 2021

Developments

Kardium raises $115-million financing round

Closely-held Kardium raised $115-million in a new financing round led by Fidelity Management & Research, together with follow-on participation by funds and accounts advised by T. Rowe Price Associates. The new...

January 25, 2021

Developments

FDA approves Aurinia’s LUPKYNIS for lupus nephritis

The FDA approved Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. LUPKYNIS is...

January 25, 2021

Developments

Soricimed approach to COVID-19 being validated by other researchers

Researchers at Rush University Medical Center in Chicago are developing a new peptide treatment to prevent COVID-19 symptoms that supports the approach being taken by closely-held Soricimed Biopharma. The peptide...

January 25, 2021

Developments

Think Research to acquire MDBriefCase Group

Think Research (TSXV:THNK) agreed to acquire closely-held MDBriefCase Group, a portfolio company of Persistence Capital Partners, for $25.3-million, mostly in stock. The transaction, which is expected to close in the...

January 20, 2021

Developments

Neuronetics Q4 preliminary revenue tops guidance

Neuronetics (NASDAQ:STIM) reported preliminary unaudited revenue for the fourth quarter of 2020 between $15-million and $15.5-million, compared with previous guidance of $13-million and $13.5-million. “During the...

January 13, 2021

Developments

Diabeloop, SFC Fluidics in U.S. development pact for Type 1 diabetes

Diabeloop and SFC Fluidics agreed to develop a Type 1 diabetes system that integrates SFC’s alternate controller-enabled (ACE) insulin pod into Diabeloop’s automated insulin delivery solution in the U.S. The new...

January 11, 2021

Developments

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

Closely-held Soricimed Biopharma and Orano Med, a nuclear biotech company based in Piano, TX entered an agreement to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers. The...

January 7, 2021

Category - Developments

Subscribe